RhoA signaling was consistently elevated in metastatic vs primary breast cancer, and in HER2-enriched, luminal A and luminal B subtypes, and may therefore be prioritized for therapy in combination with inhibitors of subtype-specific S-drivers to prevent metastatic disease. Here, ERBB2 is linked to metastatic neoplasm.